Seres Therapeutics Inc MCRB
News
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Seres Shares Down After Co Pauses Drug Development, Lays Off Workers

